A drug can make children with the most common form of dwarfism taller – but height isn’t the same as a better life

A drug that helps children with the most common form of dwarfism grow taller has sparked an ethical debate within the dwarfism community.

Some parents hope that as well as increasing size, it will prevent serious health complications and improve their children’s independence. But critics worry that a treatment focused on increasing height sends the message that dwarfism is something that needs to be corrected.

The drug, vosoritide, sold as Voxzogo, is used to treat children with achondroplasia, a genetic condition that restricts bone growth. It works by reducing the activity of a signal that slows bone growth. Approved in Europe in 2021, it is now authorised for children from four months old while their bones are still growing.

Clinical trials show that vosoritide increases growth. But whether it can prevent serious medical complications or improve quality of life in the longer term remains uncertain.

This raises difficult questions about what constitutes a successful treatment and how much say people with achondroplasia should have in deciding what those outcomes should be.

The evidence that vosoritide increases growth is now well established. Longer-term trial data show that children receiving the drug continue to grow faster than untreated children with achondroplasia over several years.

Parents may hope that treatment will also reduce some of the medical complications associated with achondroplasia, such as spinal stenosis, where narrowing of the spinal canal can put pressure on nerves, or improve independence later in life.

There is some encouraging early evidence. A 2026 trial found preliminary signs that early vosoritide treatment may improve spinal development. Another study found lower rates of some complications among children in vosoritide trials compared with published data about people who had not received the drug.

These findings are promising, but they do not yet establish whether treatment will prevent serious complications throughout life.

The spinal study followed children for only one year and included relatively small numbers, particularly when participants were divided into different age groups. Small studies make it harder to determine whether differences represent genuine treatment effects, especially for uncommon complications.

The second study included 230 children who received vosoritide, but compared their outcomes with previously published data rather than randomly assigning children to treated and untreated groups. Differences between these populations may have influenced the results.

There are also reasons for caution about assuming that starting treatment very early will prevent serious complications. Two infants who began vosoritide within days of birth still developed progressive foramen magnum stenosis, a narrowing at the base of the skull that can compress the brainstem and spinal cord. Both required surgery.